In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application ...

Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNSAssessment ...

Sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the biotech deals arena in ...

Arbutus Biotech (ABUS) heads to a key March Moderna LNP patent trial as imdusiran HBV milestones drive value—get the latest ...

The registrations for NEET 2026 have commenced. In order to appear for the MBBS entrance test, the candidates need to be well aware of the syllabus for the test. The National ...

According to Precedence Research, the global RNA analysis market size is expected to be worth USD 23.39 billion by 2035, increasing from USD 10.21 billion in 2026, with a strong CAGR of 9.65% from ...

The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA ...

By Hugo Francisco de Souza Emerging research suggests reversible RNA editing mechanisms may influence heart disease biology while opening new avenues for biomarkers and next-generation cardiovascular ...

From vaccines and diagnostics to emerging gene-based therapies, RNA molecules are now central to modern medicine. But as their use continues to grow, so does a fundamental challenge: producing RNA ...

Scientists at Rutgers University–Newark have developed a first-of-its-kind RNA-based nanotechnology that assembles itself inside living human cells and can be programmed to stop propagation of harmful ...

Under the agreement, SanegeneBio has granted Genentech exclusive worldwide rights to develop and commercialize the undisclosed program.